|
Originally published In Press as doi:10.1074/jbc.M305783200 on March 9, 2004
J. Biol. Chem., Vol. 279, Issue 20, 21658-21665, May 14, 2004
Critical Role for Hematopoietic Cell Kinase (Hck)-mediated Phosphorylation of Gab1 and Gab2 Docking Proteins in Interleukin 6-induced Proliferation and Survival of Multiple Myeloma Cells*
Klaus Podar ,
Gustavo Mostoslavsky ¶,
Martin Sattler ¶,
Yu-Tzu Tai ,
Toshiaki Hayashi ,
Laurence P. Catley ,
Teru Hideshima ,
Richard C. Mulligan ,
Dharminder Chauhan , and
Kenneth C. Anderson ||
From the
Department of Medical Oncology, Dana-Farber Cancer Institute, and the Department of Genetics, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115
Interleukin-6 (LI-6) is a known growth and survival factor in multiple myeloma via activation of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling cascade. In this report we show that Grb2-associated binder (Gab) family adapter proteins Gab1 and Gab2 are expressed by multiple myeloma cells; and that interleukin-6 induces their tyrosine phosphorylation and association with downstream signaling molecules. We further demonstrate that these events are Src family tyrosine kinase-dependent and specifically identify the role of hematopoietic cell kinase (Hck) as a new Gab family adapter protein kinase. Conversely, inhibition of Src family tyrosine kinases by the pyrazolopyrimidine PP2, as in kinase-inactive Hck mutants, significantly reduces IL-6-triggered activation of extracellular signal-regulated kinase and AKT-1, leading to significant reduction of multiple myeloma cell proliferation and survival. Taken together, these results delineate a key role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in IL-6-induced proliferation and survival of multiple myeloma cells and identify tyrosine kinases and downstream adapter proteins as potential new therapeutic targets in multiple myeloma.
Received for publication, June 2, 2003
, and in revised form, February 27, 2004.
* This work was supported by a Multiple Myeloma Research Foundation Senior Research Grant Award (to K. P.), National Institutes of Health Grant PO-1 78378, and a Doris Duke Distinguished Clinical Research Scientist award (to K. C. A.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Both authors contributed equally to this work.
|| To whom correspondence should be addressed: Dept. of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, 44 Binney St., Boston, MA 02115. Tel.: 617-632-2144; Fax: 617-632-2140; E-mail: Kenneth_Anderson{at}dfci.harvard.edu.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Agarwal, T. G. P. Bumm, A. S. Corbin, T. O'Hare, M. Loriaux, J. VanDyke, S. G. Willis, J. Deininger, K. I. Nakayama, B. J. Druker, et al.
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease
Blood,
September 1, 2008;
112(5):
1960 - 1970.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. L. Coluccia, T. Cirulli, P. Neri, D. Mangieri, M. C. Colanardi, A. Gnoni, N. Di Renzo, F. Dammacco, P. Tassone, D. Ribatti, et al.
Validation of PDGFR{beta} and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
Blood,
August 15, 2008;
112(4):
1346 - 1356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Hayakawa-Yano, K. Nishida, S. Fukami, Y. Gotoh, T. Hirano, T. Nakagawa, T. Shimazaki, and H. Okano
Epidermal Growth Factor Signaling Mediated by Grb2 Associated Binder1 Is Required for the Spatiotemporally Regulated Proliferation of Olig2-Expressing Progenitors in the Embryonic Spinal Cord
Stem Cells,
June 1, 2007;
25(6):
1410 - 1422.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ni, C. Zhao, G.-S. Feng, R. F. Paulson, and P. H. Correll
A Novel Stat3 Binding Motif in Gab2 Mediates Transformation of Primary Hematopoietic Cells by the Stk/Ron Receptor Tyrosine Kinase in Response to Friend Virus Infection
Mol. Cell. Biol.,
May 15, 2007;
27(10):
3708 - 3715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Podar, G. Tonon, M. Sattler, Y.-T. Tai, S. LeGouill, H. Yasui, K. Ishitsuka, S. Kumar, R. Kumar, L. N. Pandite, et al.
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
PNAS,
December 19, 2006;
103(51):
19478 - 19483.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. V. Parry, G. C. Whittaker, M. Sims, C. E. Edmead, M. J. Welham, and S. G. Ward
Ligation of CD28 Stimulates the Formation of a Multimeric Signaling Complex Involving Grb-2-Associated Binder 2 (Gab2), Src Homology Phosphatase-2, and Phosphatidylinositol 3-Kinase: Evidence That Negative Regulation of CD28 Signaling Requires the Gab2 Pleckstrin Homology Domain
J. Immunol.,
January 1, 2006;
176(1):
594 - 602.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson
Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6345 - 6350.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|